{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6"},{"groupId":"OG001","value":"78.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1338"},{"groupId":"OG001","value":"1335"}],"units":"Participants"}],"description":"Percentage of patients who did not experience an event where events are defined as death from any cause.","groups":[{"description":"Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.\n\noxaliplatin: Given IV\n\nleucovorin calcium: Given IV\n\nfluorouracil: Given IV","id":"OG000","title":"Arm I (mFOLFOX6)"},{"description":"Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.\n\noxaliplatin: Given IV\n\nleucovorin calcium: Given IV\n\nfluorouracil: Given IV\n\nbevacizumab: Given IV","id":"OG001","title":"Arm II (Bevacizumab, mFOLFOX6)"}],"paramType":"NUMBER","populationDescription":"Survival analysis was done 2 years after Disease Free Survival analysis. For Arm 2 one additional patient had follow up at the later analysis.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients"}